Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Signals Further Clinical Trial Policy Tightening

Executive Summary

The nation’s top drug regulator vows to adopt ICH’s guidelines on drug safety and efficacy, after dropping the industry a bombshell with the tightening of oncology drug clinical trials a week ago.

You may also be interested in...



China Reins In Cancer Drug Trials, Stressing Patient Needs and Benefits

China's drug regulatory authority is taking aim at strengthening randomized, controlled clinical trials conducted domestically for cancer drugs, leaving biotech stocks reeling from the proposed stricter requirements.

Regulators Moving Ahead Of Industry In China? Officials, Execs Weigh In

While regulators are steaming ahead to accelerate clinical trial and product approvals, China's pharma industry still lacks innovation. Underlying the hot investment, multi-million deals and IPOs is a lingering reliance on 'fast-following,' regulators and pharma execs tell the DIA China meeting.

Chinese Biotechs' Foray Into mRNA Enters New Chapter With $100m Everest Deal

Everest Medicines’ deal with Canadian biotech Providence Therapeutics contains a full transfer of technology which may be appealing to Chinese regulators.

Topics

Related Companies

UsernamePublicRestriction

Register

PS144626

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel